In vitro and in vivo inhibition of the T315I mutant BCR/ABL kinase.

被引：2

作者：

Zhu, Hong ^{[1
]}

Hanna, Ehab ^{[1
]}

Lohse, Dan ^{[1
]}

Stoughton, Silva ^{[1
]}

Tam, Betty ^{[1
]}

Barrett, Kathy ^{[1
]}

Noronha, Glenn ^{[1
]}

Dneprovskaia, Elena ^{[1
]}

Cao, Jon ^{[1
]}

Chow, Chun ^{[1
]}

Hwang, Linda ^{[1
]}

Mak, Chiching ^{[1
]}

McPherson, Andy ^{[1
]}

Palanki, Moorthy ^{[1
]}

Pathak, Ved P. ^{[1
]}

Renick, Joe ^{[1
]}

Soil, Richard ^{[1
]}

Zeng, Binqi ^{[1
]}

Hood, John ^{[1
]}

机构：

[1] TargeGen Inc, San Diego, CA USA

来源：

BLOOD | 2006年 / 108卷 / 11期

关键词：

D O I：

10.1182/blood.V108.11.2182.2182

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2182

引用

页码：619A / 619A

页数：1

共 50 条

[41] AXITINIB Targets Gatekeeper-Mutant BCR-ABL1(T315I)-Driven Leukemia in a Distinct And Selective Fashion
Pemovska, T.
Johnson, E.
Kontro, M.
Repasky, G. A.
Chen, J.
Wells, P.
Cronin, C.
McTigue, M.
Kallioniemi, O.
Porkka, K.
Murray, B. W.
Wennerberg, K.
ANNALS OF HEMATOLOGY, 2015, 94 : S90 - S91
[42] AXITINIB Targets Gatekeeper-Mutant BCR-ABL1(T315I)-Driven Leukemia in a Distinct And Selective Fashion
Pemovska, T.
Johnson, E.
Kontro, M.
Repasky, G. A.
Chen, J.
Wells, P.
Cronin, C.
McTigue, M.
Kallioniemi, O.
Porkka, K.
Murray, B. W.
Wennerberg, K.
ANNALS OF HEMATOLOGY, 2015, 94 (SUPPL 1) : 90 - 91
[43] Axitinib targets gatekeeper-mutant BCR-ABL1(T315I)-driven leukemia in a distinct and selective fashion
Pemovska, Tea
Johnson, Eric
Kontro, Mika
Repasky, Gretchen A.
Chen, Jeffrey
Wells, Peter
Cronin, Ciaran N.
McTigue, Michele
Kallioniemi, Olli
Porkka, Kimmo
Murray, Brion W.
Wennerberg, Krister
CANCER RESEARCH, 2015, 75
[44] Inhibition of BCR/ABL-T315I by Dismantling the Hydrophobic Spine
Azam, Mohammad
Seeliger, MarIcus
Powers, John T.
Gray, Nathanael
Kuriyan, John
Daley, George Q.
BLOOD, 2008, 112 (11) : 742 - 742
[45] The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
You, Liangshun
Liu, Hui
Huang, Jian
Xie, Wanzhuo
Wei, Jueying
Ye, Xiujin
Qian, Wenbin
ONCOTARGET, 2017, 8 (05) : 7777 - 7790
[46] Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation
Liang Jiang
Yuting Wang
Qian Lia
Zhengchao Tu
Sihua Zhu
Sanfang Tu
Zhang Zhang
Ke Ding
Xiaoyun Lu
ActaPharmaceuticaSinicaB, 2021, 11 (05) : 1315 - 1328
[47] Recent Developments in the Third Generation Inhibitors of Bcr-Abl for Overriding T315I Mutation
Lu, X. Y.
Cai, Q.
Ding, K.
CURRENT MEDICINAL CHEMISTRY, 2011, 18 (14) : 2146 - 2157
[48] Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation
Tea Pemovska
Eric Johnson
Mika Kontro
Gretchen A. Repasky
Jeffrey Chen
Peter Wells
Ciarán N. Cronin
Michele McTigue
Olli Kallioniemi
Kimmo Porkka
Brion W. Murray
Krister Wennerberg
Nature, 2015, 519 : 102 - 105
[49] Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation
Jiang, Liang
Wang, Yuting
Li, Qian
Tu, Zhengchao
Zhu, Sihua
Tu, Sanfang
Zhang, Zhang
Ding, Ke
Lu, Xiaoyun
ACTA PHARMACEUTICA SINICA B, 2021, 11 (05) : 1315 - 1328
[50] Ponatinib, a pan-Bcr-Abl kinase inhibitor approved for leukemia treatment, potently inhibits the T315I mutant and overcomes mutation-based resistance
Huang, Wei-Sheng
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249

← 1 2 3 4 5 →